Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19^*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

Table 4

Characteristics of three different CYP2C19*2 genotyped subjects at baseline and the end of the test.

	CYP2C19*1/*1 (𝑛=6)		𝑃 value	CYP2C19*1/*2 (𝑛=6)		𝑃 value	CYP2C19*2/*2 (𝑛=6)		𝑃 value
	Baseline	The end		Baseline	The end		Baseline	The end
Hb (g/L)	144.5±15.5	145.7±13.6	.428	144.7±15.3	144.7±16.3	1.000	147.2±5.2	150±6.9	.467
FSG (mmol/L)	4.9±0.2	5.1±0.6	.722	5.5±1.0	5.2±1.3	.437	5.3±0.8	5.3±0.7	1.000
ALT (μ/L)	37.2±2.1	37.2±2.3	1.000	38.0±0.9	37.0±3.3	.414	37.3±1.9	37.2±1.2	.921
AST (μ/L)	35.7±2.3	36.3±2.8	.171	36.6±2.7	36.7±1.8	.855	37.9±1.2	36.8±2.4	.309
CGCCr (ml/min)	88.67±2.5	101.6±9.9	.017	103.2±14.3	92.0±4.3	.099	94.4±8.5	88.5±5.5	.060
TC (mmol/L)	4.9±0.5	4.8±0.6	.782	4.5±0.9	4.6±0.7	.472	4.4±0.6	4.2±0.5	.398

Note: values are presented as mean ± SD. The 𝑃 values are for comparison to baseline.